DE602004029934D1 - Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament - Google Patents
Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikamentInfo
- Publication number
- DE602004029934D1 DE602004029934D1 DE602004029934T DE602004029934T DE602004029934D1 DE 602004029934 D1 DE602004029934 D1 DE 602004029934D1 DE 602004029934 T DE602004029934 T DE 602004029934T DE 602004029934 T DE602004029934 T DE 602004029934T DE 602004029934 D1 DE602004029934 D1 DE 602004029934D1
- Authority
- DE
- Germany
- Prior art keywords
- receptor
- antibody against
- chemocin
- ccr4
- genetically modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003406590 | 2003-12-04 | ||
JP2004155141 | 2004-05-25 | ||
PCT/JP2004/018430 WO2005053741A1 (ja) | 2003-12-04 | 2004-12-03 | ケモカイン受容体ccr4に対する遺伝子組換え抗体を含む医薬 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004029934D1 true DE602004029934D1 (de) | 2010-12-16 |
Family
ID=34656222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004029934T Active DE602004029934D1 (de) | 2003-12-04 | 2004-12-03 | Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament |
Country Status (8)
Country | Link |
---|---|
US (2) | US8491902B2 (de) |
EP (1) | EP1702625B1 (de) |
JP (1) | JPWO2005053741A1 (de) |
AT (1) | ATE486611T1 (de) |
AU (1) | AU2004294842B2 (de) |
CA (1) | CA2548454C (de) |
DE (1) | DE602004029934D1 (de) |
WO (1) | WO2005053741A1 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2401491C (en) * | 2000-03-03 | 2011-07-05 | Kyowa Hakko Kogyo Co., Ltd. | Ccr4-binding antibody and diagnostic and therapeutic uses thereof |
DE60238503D1 (de) * | 2001-08-31 | 2011-01-13 | Kyowa Hakko Kirin Co Ltd | Mit humanem cdr gepfropfte antikörper und antikörperfragmente davon |
US20070172476A1 (en) * | 2005-07-28 | 2007-07-26 | Kyowa Hakko Kogyo Co., Ltd. | Method of treating B-cell neoplasms or Hodgkin's lymphoma |
CA2675426A1 (en) * | 2007-02-15 | 2008-08-21 | The Procter & Gamble Company | Benefit agent delivery compositions |
GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
US8962806B2 (en) | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
JP5709061B2 (ja) * | 2009-09-10 | 2015-04-30 | 協和発酵キリン株式会社 | ヒトccケモカイン受容体4(ccr4)に特異的に結合する抗体組成物を含む医薬 |
EP3309245A1 (de) | 2009-12-18 | 2018-04-18 | The Procter & Gamble Company | Verkapselungen |
ES2758884T3 (es) | 2011-06-24 | 2020-05-06 | Stephen D Gillies | Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas |
MX2014011397A (es) | 2012-04-10 | 2014-11-25 | Procter & Gamble | Composiciones para reducir el mal olor. |
BR112015000068A2 (pt) * | 2012-07-06 | 2017-08-08 | Kyowa Hakko Kirin Co Ltd | método terapêutico e medicamento para mielopatia associada a htlv-1 (ham) |
US11110196B2 (en) | 2013-08-01 | 2021-09-07 | The Procter & Gamble Company | Articles comprising malodor reduction compositions |
MX2016015181A (es) | 2014-05-21 | 2017-05-25 | Pfizer | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. |
US20160092661A1 (en) | 2014-09-26 | 2016-03-31 | The Procter & Gamble Company | Method of making perfumed goods |
MX2018000074A (es) | 2015-06-22 | 2018-03-16 | Procter & Gamble | Composiciones de perfume. |
EP3313361B1 (de) | 2015-06-29 | 2023-09-13 | Takasago International Corporation | Moschuszusammensetzungen und methoden zu deren anwendung |
WO2017165615A1 (en) | 2016-03-24 | 2017-09-28 | The Procter & Gamble Company | Hair care compositions comprising malodor reduction compositions |
EP3471754A1 (de) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1-antikörper |
CN111278417A (zh) | 2017-10-10 | 2020-06-12 | 宝洁公司 | 含低无机盐的无硫酸盐澄清个人清洁组合物 |
AU2018360766A1 (en) | 2017-11-06 | 2020-05-21 | Rapt Therapeutics, Inc. | Anticancer agents |
US10792384B2 (en) | 2017-12-15 | 2020-10-06 | The Procter & Gamble Company | Rolled fibrous structures comprising encapsulated malodor reduction compositions |
CA3159404A1 (en) | 2019-12-06 | 2021-06-10 | The Procter & Gamble Company | Sulfate free composition with enhanced deposition of scalp active |
WO2021173203A1 (en) | 2020-02-27 | 2021-09-02 | The Procter & Gamble Company | Anti-dandruff compositions with sulfur having enhanced efficacy and aesthetics |
AU2021249888A1 (en) | 2020-04-01 | 2022-10-27 | Kyowa Kirin Co., Ltd. | Antibody composition |
JP2023549517A (ja) | 2020-12-04 | 2023-11-27 | ザ プロクター アンド ギャンブル カンパニー | 悪臭低減物質を含むヘアケア組成物 |
US11771635B2 (en) | 2021-05-14 | 2023-10-03 | The Procter & Gamble Company | Shampoo composition |
US11986543B2 (en) | 2021-06-01 | 2024-05-21 | The Procter & Gamble Company | Rinse-off compositions with a surfactant system that is substantially free of sulfate-based surfactants |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6498015B1 (en) | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US6762174B1 (en) * | 1998-02-24 | 2004-07-13 | Dovetail Technologies, Inc. | Low molecular weight compounds administered together with anti-cancer agents to prevent or treat cancer and pharmaceutical compositions thereof |
US6488930B1 (en) * | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
US6245332B1 (en) | 1999-01-15 | 2001-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of systemic memory T cell trafficking |
CA2401491C (en) * | 2000-03-03 | 2011-07-05 | Kyowa Hakko Kogyo Co., Ltd. | Ccr4-binding antibody and diagnostic and therapeutic uses thereof |
MXPA03001039A (es) * | 2000-08-02 | 2004-09-10 | Johnson & Johnson | Quimioterapia anti-viral y anti-tumor mejorada mediante administracion de eritropoeitina. |
US6759045B2 (en) | 2000-08-08 | 2004-07-06 | Immunomedics, Inc. | Immunotherapy for chronic myelocytic leukemia |
MXPA03002974A (es) | 2000-10-06 | 2004-05-05 | Kyowa Hakko Kogyo Kk | Celulas que producen composiciones de anticuerpo. |
JP2005501530A (ja) | 2001-06-08 | 2005-01-20 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 体細胞株におけるヒトインスリンのグルコース−調節された産生のために有用な核酸構築物 |
DE60238503D1 (de) * | 2001-08-31 | 2011-01-13 | Kyowa Hakko Kirin Co Ltd | Mit humanem cdr gepfropfte antikörper und antikörperfragmente davon |
JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
-
2004
- 2004-12-03 JP JP2005516040A patent/JPWO2005053741A1/ja active Pending
- 2004-12-03 US US10/581,413 patent/US8491902B2/en active Active
- 2004-12-03 AT AT04801651T patent/ATE486611T1/de not_active IP Right Cessation
- 2004-12-03 AU AU2004294842A patent/AU2004294842B2/en not_active Ceased
- 2004-12-03 DE DE602004029934T patent/DE602004029934D1/de active Active
- 2004-12-03 WO PCT/JP2004/018430 patent/WO2005053741A1/ja active Application Filing
- 2004-12-03 CA CA2548454A patent/CA2548454C/en active Active
- 2004-12-03 EP EP04801651A patent/EP1702625B1/de active Active
-
2013
- 2013-06-17 US US13/919,771 patent/US9675625B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9675625B2 (en) | 2017-06-13 |
CA2548454A1 (en) | 2005-06-16 |
CA2548454C (en) | 2013-12-31 |
AU2004294842A1 (en) | 2005-06-16 |
US20130295045A1 (en) | 2013-11-07 |
JPWO2005053741A1 (ja) | 2007-06-28 |
US8491902B2 (en) | 2013-07-23 |
EP1702625B1 (de) | 2010-11-03 |
US20070020263A1 (en) | 2007-01-25 |
AU2004294842B2 (en) | 2010-05-13 |
EP1702625A1 (de) | 2006-09-20 |
WO2005053741A1 (ja) | 2005-06-16 |
ATE486611T1 (de) | 2010-11-15 |
EP1702625A4 (de) | 2008-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004029934D1 (de) | Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament | |
CY1118849T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
CY1118179T1 (el) | Φαρμακευτικη συνθεση | |
CY1117387T1 (el) | ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ | |
DK1083879T3 (da) | Indretninger til at tilvejebringe forlænget medikamentterapi | |
ATE432289T1 (de) | Glp-1 und behandlungsmethode für diabetes | |
CO5640087A2 (es) | Composiciones de farmacos anti-inflamatorios no esteroideos descongestionantes y anti-histaminicos | |
IS7431A (is) | Samrunaefnasambönd lyfja eða frumudrepandi efna og líffræðilega virkra peptíða | |
CY1109122T1 (el) | Μηχανισμος εμφανισης δοσολογιας για μια συσκευη χορηγησης φαρμακου | |
EA200601253A1 (ru) | Преимущественно линейная шипучая лекарственная форма фентанила для перорального применения и способы введения | |
CR9842A (es) | Composiciones de celecoxib | |
NO20053077D0 (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
BR0206160A (pt) | Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos | |
DE60238503D1 (de) | Mit humanem cdr gepfropfte antikörper und antikörperfragmente davon | |
CY1108430T1 (el) | Χρηση ανταγωνιστων διαυλου νευρωνικου νατριου μαζι με αμιτραζ για τον ελεγχο εκτοπαρασιτων σε ομοιοθερμικα ζωα | |
WO2004017896A3 (en) | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist | |
DK1781277T3 (da) | Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol | |
ATE516366T1 (de) | Regulierte aptamer-therapeutika | |
TR200002969T2 (tr) | Farmasötik bileşim. | |
ATE413187T1 (de) | Pharmazeutische zusammensetzungen mit interferon- tau | |
BRPI0412430A (pt) | polipeptìdeo agonista do receptor de zot e zonulina | |
DE502004010644D1 (de) | Geschmacksstoffhaltige arzneimittelformulierungen mit verbesserten pharmazeutischen eigenschaften | |
DE60141297D1 (de) | Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper | |
EA200500764A1 (ru) | Фармацевтические композиции и лекарственные формы для трансбуккальной и сублингвальной доставки тизанидина и способы введения тизанидина сублингвально или трансбуккально | |
CY1110368T1 (el) | Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη |